Showing results (71-80 of 85) with videos related to

Sort By:
Pageof 9
Vaccines|November 11, 2022
A Case Report of Monkeypox in an Adult Patient from Italy: Clinical and Dermoscopic Manifestations, Diagnosis and ManagementIlaria Proietti, Paolo Emilio Santoro, Nevena Skroza, et al.
Italian Journal of Dermatology and Venereology|April 8, 2026
Comparing the clinical response and patient satisfaction of foam versus cream calcipotriol-betamethasone dipropionate treatment of localized plaque psoriasisPietro Scribani Rossi, Nicoletta Bernardini, Giuseppe Gemma, et al.
Journal of Clinical Medicine|July 27, 2022
Similar Levels of Efficacy of Two Different Maintenance Doses of Adalimumab on Clinical Severity and Quality of Life of Patients with Hidradenitis SuppurativaLuca Fania, Giulia Giovanardi, Tonia Samela, et al.
The Journal of Dermatological Treatment|February 27, 2024
Efficacy and safety of tildrakizumab in elderly patients: real-world multicenter study (ESTER - study)Diego Orsini, Giacomo Caldarola, Annunziata Dattola, et al.
Dermatology Practical & Conceptual|March 21, 2025
Risankizumab Versus Secukinumab: A Real-World Efficacy and Cost per Responder Comparison in Patients With Psoriasis in ItalyFederico Pirro, Giacomo Caldarola, Nicoletta Bernardini, et al.
Dermatology and Therapy|April 16, 2025
Predictive Factors for Super Responder Status and Long-Term Effectiveness of Guselkumab in Psoriasis: A Multicenter Retrospective StudyEdoardo Mortato, Marina Talamonti, Lorenzo Marcelli, et al.
Clinical and Experimental Dermatology|April 16, 2025
A Long-Term Real-Life Safety Study of Guselkumab in Psoriasis Patients with Infectious Comorbidities, Malignancies or Heart Disease: The EARLY StudyEdoardo Mortato, Marina Talamonti, Lorenzo Marcelli, et al.
Psoriasis (Auckland, N.Z.)|September 22, 2025
Long-Term Real-World Effectiveness and Drug Survival of Guselkumab in Patients with Psoriasis: A 5-Year Retrospective StudyEdoardo Mortato, Marina Talamonti, Lorenzo Marcelli, et al.
Expert Opinion on Biological Therapy|June 16, 2022
Real-world outcomes in patients with moderate-to-severe plaque psoriasis treated with guselkumab for up to 1 yearMarco Galluzzo, Marina Talamonti, Nicoletta Bernardini, et al.
The Journal of Dermatological Treatment|September 24, 2025
Psoriasis severity, comorbidity burden, and biologic therapy: a multicenter observational study using the Charlson Comorbidity IndexNicoletta Bernardini, Annunziata Dattola, Giuseppe Paolo Antonio Gemma, et al.
Pageof 9